Confounding factors affecting the National Institutes of Health (NIH) chronic Graft-Versus-Host Disease Organ-Specific Score and global severity

被引:14
|
作者
Aki, S. Z. [1 ,2 ]
Inamoto, Y. [1 ]
Carpenter, P. A. [1 ,3 ]
Storer, B. E. [1 ,3 ]
Sandmaier, B. M. [1 ,3 ]
Lee, S. J. [1 ,3 ]
Martin, P. J. [1 ,3 ]
Flowers, M. E. D. [1 ,3 ]
机构
[1] Fred Hutchinson Canc Res Ctr, Div Climate Res, Seattle, WA USA
[2] Gazi Univ, Fac Med, Dept Hematol, Ankara, Turkey
[3] Univ Washington, Div Med Oncol, Seattle, WA USA
基金
美国国家卫生研究院;
关键词
CONSENSUS DEVELOPMENT PROJECT; CHRONIC GVHD CONSORTIUM; WORKING GROUP-REPORT; CLINICAL-TRIALS; UNRELATED DONOR; BONE-MARROW; CRITERIA; OUTCOMES; TRANSPLANTATION; MORTALITY;
D O I
10.1038/bmt.2016.131
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
The 2005 NIH chronic GVHD (cGVHD) organ severity is based on the assessment of current status regardless of whether abnormalities are due to GVHD. The score assignment does not require knowledge of past manifestations, attribution or whether cGVHD is still active. The aim of this study is to describe confounding factors affecting organ scores in patients with cGVHD. The study included 189 consecutive cGVHD patients evaluated at our center in 2013. Providers completed the NIH 0-3 organ-specific scoring evaluation with two questions added for each organ to identify abnormalities that were (i) not attributed to cGVHD or (ii) attributed to cGVHD plus other causes. Abnormalities attributed to causes other than GVHD were recorded. Eighty (14%) abnormalities were not attributed to cGVHD in at least one organ, and 41 (7%) abnormalities were attributed to cGVHD plus other causes in at least one organ. A total of 436 (78%) abnormalities were attributed only to cGVHD. Abnormalities not attributed to cGVHD were observed most frequently in the lung, gastrointestinal tract and skin. Most common abnormalities included pre-transplant condition, sequelae from GVHD, deconditioning, infections and medications. Our results support the 2014 NIH consensus recommendation to consider attribution when scoring organ abnormalities.
引用
收藏
页码:1350 / 1353
页数:4
相关论文
共 50 条
  • [21] KINETIC AND ORGAN-SPECIFIC PATTERNS OF CYTOKINE EXPRESSION IN ACUTE GRAFT-VERSUS-HOST DISEASE
    BAKER, KS
    ALLEN, RD
    ROTHS, JB
    SIDMAN, CL
    BONE MARROW TRANSPLANTATION, 1995, 15 (04) : 595 - 603
  • [22] The global severity of chronic graft-versus-host disease, determined by National Institutes of Health consensus criteria, is associated with overall survival and non-relapse mortality
    Pidala, Joseph
    Kim, Jongphil
    Anasetti, Claudio
    Nishihori, Taiga
    Betts, Brian
    Field, Teresa
    Perkins, Janelle
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2011, 96 (11): : 1678 - 1684
  • [23] The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease
    Cooke, Kenneth R.
    Luznik, Leo
    Sarantopoulos, Stefanie
    Hakim, Frances T.
    Jagasia, Madan
    Fowler, Daniel H.
    van den Brink, Marcel R. M.
    Hansen, John A.
    Parkman, Robertson
    Miklos, David B.
    Martin, Paul J.
    Paczesny, Sophie
    Vogelsang, Georgia
    Pavletic, Steven
    Ritz, Jerome
    Schultz, Kirk R.
    Blazar, Bruce R.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2017, 23 (02) : 211 - 234
  • [24] Histopathologic diagnosis of chronic graft-versus-host disease of the oral mucosa according to the National Institutes of Health Consensus
    da Silva Santos, Paulo Sergio
    Coracin, Fabio Luiz
    de Almeida Barros, Jose Carlos
    Cury Gallottini, Marina Helena
    EINSTEIN-SAO PAULO, 2014, 12 (02): : 204 - 210
  • [25] Establishing a standardized system to capture chronic graft-versus-host disease (GVHD) data in accordance to the national institutes (NIH) consensus criteria
    Dierov, D.
    Ciolino, C.
    Fatmi, S.
    Mosesso, K.
    Nieves, J.
    Prockop, S.
    Perales, M-A
    Webb, N.
    Doris, P.
    BONE MARROW TRANSPLANTATION, 2017, 52 : S102 - S102
  • [26] Impact of NIH global scoring system of chronic graft-versus-host disease on relapse incidence
    Moon, J. H.
    Sohn, S. K.
    Uhm, J.
    Gupta, V.
    Lipton, J. H.
    Messner, H. A.
    Kim, D.
    BONE MARROW TRANSPLANTATION, 2013, 48 : S436 - S437
  • [27] Chronic graft-versus-host disease: implications of the National Institutes of Health consensus development project on criteria for clinical trials
    Pavletic, S. Z.
    Lee, S. J.
    Socie, G.
    Vogelsang, G.
    BONE MARROW TRANSPLANTATION, 2006, 38 (10) : 645 - 651
  • [28] Feasibility of NIH consensus criteria for chronic graft-versus-host disease
    Cho, B-S
    Min, C-K
    Eom, K-S
    Kim, Y-J
    Kim, H-J
    Lee, S.
    Cho, S-G
    Kim, D-W
    Lee, J-W
    Min, W-S
    Kim, C-C
    LEUKEMIA, 2009, 23 (01) : 78 - 84
  • [29] Chronic graft-versus-host disease: implications of the National Institutes of Health consensus development project on criteria for clinical trials
    S Z Pavletic
    S J Lee
    G Socie
    G Vogelsang
    Bone Marrow Transplantation, 2006, 38 : 645 - 651
  • [30] The Future of Chronic Graft-Versus-Host Disease: Introduction to the 2020 National Institutes of Health Consensus Development Project Reports
    Pavletic, Steven Z.
    Martin, Paul J.
    Schultz, Kirk R.
    Lee, Stephanie J.
    TRANSPLANTATION AND CELLULAR THERAPY, 2021, 27 (06): : 448 - 451